Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2025-12-31 @ 1:33 PM
Study NCT ID:
NCT04295005
Status:
COMPLETED
Last Update Posted:
2024-08-30
First Post:
2020-03-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-11-16
Start Date Type:
ACTUAL
Primary Completion Date:
2021-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-09-30
Completion Date Type:
ACTUAL
First Submit Date:
2020-03-03
First Submit QC Date:
None
Study First Post Date:
2020-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-09-26
Results First Submit QC Date:
None
Results First Post Date:
2024-08-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-08
Last Update Post Date:
2024-08-30
Last Update Post Date Type:
ACTUAL